Roxadustat: Not just for anemia
Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent studies found it also has potential for the treatment of other hypoxia-related diseases. Although clinical studies have...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.971795/full |
| _version_ | 1811183159992123392 |
|---|---|
| author | Xiaoyu Zhu Lili Jiang Xuejiao Wei Mengtuan Long Yujun Du |
| author_facet | Xiaoyu Zhu Lili Jiang Xuejiao Wei Mengtuan Long Yujun Du |
| author_sort | Xiaoyu Zhu |
| collection | DOAJ |
| description | Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent studies found it also has potential for the treatment of other hypoxia-related diseases. Although clinical studies have not yet found significant adverse or off-target effects of roxadustat, clinicians must be vigilant about these possible effects. Hypoxia-inducible factor regulates the expression of many genes and physiological processes in response to a decreased level of oxygen, but its role in the pathogenesis of different diseases is complex and controversial. In addition to increasing the expression of hypoxia-inducible factor, roxadustat also has some effects that may be HIF-independent, indicating some potential off-target effects. This article reviews the pharmacological characteristics of roxadustat, its current status in the treatment of renal anemia, and its possible effects on other pathological mechanisms. |
| first_indexed | 2024-04-11T09:43:09Z |
| format | Article |
| id | doaj.art-75412d6dc6f740cbbb46573c3f800b51 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T09:43:09Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-75412d6dc6f740cbbb46573c3f800b512022-12-22T04:31:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.971795971795Roxadustat: Not just for anemiaXiaoyu Zhu0Lili Jiang1Xuejiao Wei2Mengtuan Long3Yujun Du4Department of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, ChinaPhysical Examination Center, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, ChinaRoxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent studies found it also has potential for the treatment of other hypoxia-related diseases. Although clinical studies have not yet found significant adverse or off-target effects of roxadustat, clinicians must be vigilant about these possible effects. Hypoxia-inducible factor regulates the expression of many genes and physiological processes in response to a decreased level of oxygen, but its role in the pathogenesis of different diseases is complex and controversial. In addition to increasing the expression of hypoxia-inducible factor, roxadustat also has some effects that may be HIF-independent, indicating some potential off-target effects. This article reviews the pharmacological characteristics of roxadustat, its current status in the treatment of renal anemia, and its possible effects on other pathological mechanisms.https://www.frontiersin.org/articles/10.3389/fphar.2022.971795/fullroxadustathypoxia-inducible factorrenal anemiafibrosismetabolisminflammation |
| spellingShingle | Xiaoyu Zhu Lili Jiang Xuejiao Wei Mengtuan Long Yujun Du Roxadustat: Not just for anemia Frontiers in Pharmacology roxadustat hypoxia-inducible factor renal anemia fibrosis metabolism inflammation |
| title | Roxadustat: Not just for anemia |
| title_full | Roxadustat: Not just for anemia |
| title_fullStr | Roxadustat: Not just for anemia |
| title_full_unstemmed | Roxadustat: Not just for anemia |
| title_short | Roxadustat: Not just for anemia |
| title_sort | roxadustat not just for anemia |
| topic | roxadustat hypoxia-inducible factor renal anemia fibrosis metabolism inflammation |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.971795/full |
| work_keys_str_mv | AT xiaoyuzhu roxadustatnotjustforanemia AT lilijiang roxadustatnotjustforanemia AT xuejiaowei roxadustatnotjustforanemia AT mengtuanlong roxadustatnotjustforanemia AT yujundu roxadustatnotjustforanemia |